
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and remain a top public health priority. Antiretroviral therapy (ART) has been effective in extending lives, but at a cost of lifelong adherence to treatment. Broadly neutralizing antibodies (bNAbs) are directed to conserved regions of the HIV-1 envelope glycoprotein trimer (Env) and can block infection if present at the time of viral exposure. The therapeutic application of bNAbs holds great promise, and progress is being made toward their development for widespread clinical use. Compared to the current standard of care of small molecule-based ART, bNAbs offer: (1) reduced toxicity; (2) the advantages of extended half-lives that would bypass daily dosing requirements; and (3) the potential to incorporate a wider immune response through Fc signaling. Recent advances in discovery technology can enable system-wide mining of the immunoglobulin repertoire and will continue to accelerate isolation of next generation potent bNAbs. Passive transfer studies in pre-clinical models and clinical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and achieving viral suppression.
These studies have helped to define the window of opportunity for optimal intervention to achieve viral clearance, either using bNAbs alone or in combination with ART. None of these advances with bNAbs would be possible without technological advancements and expanding the cohorts of donor participation. Together these elements fueled the remarkable growth in bNAb development. Here, we review the development of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal models and early clinical trials, and innovations to optimize their clinical potential through efforts to extend half-life, maximize the contribution of Fc effector functions, preclude escape through multiepitope targeting, and the potential for sustained delivery.
Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers
Aim: In Germany, the willingness to be vaccinated against COVID-19 is rather low among medical staff. We collected data on symptoms, antibody titers and vaccination readiness from clinic employees at a municipal clinic who had already been through a COVID-19 infection (asymptomatic to moderate). We also examined the antibody titers for their possible importance as an individual decision-making aid with regard to vaccination.
Method: 200 employees of our municipal clinics were included in the study. COVID-19 antibody determination was performed using an ELISA (EUROIMMUN™, PerkinElmer, Inc. Company). The participants were given an anonymous questionnaire containing anthropometrical issues, symptoms of the infection and questions concerning the vaccination decision. Finally, the antibody levels were reported to the participants and the attitude towards a vaccination was reevaluated.
Results: In all 200 participants who had already gone through a COVID-19 infection, 75 employees were in favor of a vaccination (37.5%), 96 were opposed to vaccination (48%), and 29 were undecided (14.5%). In the different occupational groups, the positive trend in terms of willingness to be vaccinated was highest among physicians and is least among nurses. The antibody results showed considerable variation in titer levels and therefore did not correlate with disease severity in asymptomatic to moderately ill persons. We also observed a pro-vaccination trend with increasing age of the participants. The specifically-asked symptom of cutaneous hyperesthesia during COVID-19 infection occurred in 5% of the participants.
Conclusion: In medical personnel who had already suffered from a COVID-19 infection, the willingness to receive a vaccination tends to be highest among physicians, and lowest in nurses, and increases with age. For the vast majority of those affected, knowledge of the antibody titers only reinforces the vaccination decision made beforehand and thus does not contribute to a change in vaccination decision. The specifically-requested symptom of cutaneous hyperesthesia during COVID-19 infection was unexpectedly frequent.

Engineering a novel IgG-like bispecific antibody against enterovirus A71
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection. The development of monoclonal antibodies (mAbs) has demonstrated promise as a novel therapy for the prevention and treatment of infectious diseases. Several medical conditions have been treated using bispecific or multi-specific antibodies that recognize two or more distinct epitopes simultaneously. However, bispecific or multi-specific antibodies often encounter protein expression and product stability problems.
In this study, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral activity compared with E18 or F1. Additionally, E18-F1 not only improved survival rate, but also reduced clinical signs in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a lethal dose of EVA71. Altogether, our results reveal that E18-F1 is a simple format bispecific antibody with promising antiviral activity for EVA71.
Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis prior to the Onset of Optic Neuritis
We herein report a case of myelin oligodendrocyte glycoprotein-antibody-associated disorder (MOG-AD) presenting with corticomeningeal encephalitis. The patient exhibited oral ulceration, a mild impairment of consciousness, fever, nausea, nuchal rigidity, positivity for human leukocyte antigen type B51, and neutrophil-dominant pleocytosis and interleukin-6 level in cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) revealed a right temporal lesion with leptomeningeal gadolinium enhancement.
The initial diagnosis was neuro-Behçet’s disease presenting with meningoencephalitis; however, a cell-based assay detected anti-MOG antibody in the serum and CSF and the patient also experienced bilateral optic neuritis. After administering steroid therapy, his neurologic symptoms and CSF abnormalities improved along with the disappearance of gadolinium enhancement and the lesion on MRI. This case suggests that MOG-AD may present with corticomeningeal encephalitis prior to the onset of optic neuritis.
![]() Anti-VEGF antibody |
|||
PAab09391 | Lifescience Market | 100 ug | EUR 463.2 |
![]() anti- VEGF antibody |
|||
FNab09391 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VEGF |
![]() Anti- VEGF antibody |
|||
FNab09933 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VEGF |
![]() Anti-VEGF antibody |
|||
STJ97787 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to VEGF. |
![]() Anti-VEGF antibody |
|||
STJ119887 | St John's Laboratory | 100 µl | EUR 471.6 |
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. |
![]() Polyclonal Goat anti-GST α-form |
|||
GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
![]() Polyclonal Goat anti-GST μ-form |
|||
GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
![]() Polyclonal Goat anti-GST p-form |
|||
GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
![]() Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin |
|||
1-CSB-EP606027NAH | Cusabio |
|
|
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli |
![]() Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug |
|||
7422-MSM1-P1 | EnQuireBio | 100ug | EUR 513.6 |
![]() Anti-VEGF-C Antibody |
|||
A00623 | BosterBio | 100ul | EUR 476.4 |
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat. |
![]() Anti-VEGF/Vegfa Antibody |
|||
A00045 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF/VEGF164 Antibody |
|||
A00045-1 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF/Vegfa Antibody |
|||
A00045-2 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF/VEGFA Antibody |
|||
PA1080 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF/VEGFA Antibody |
|||
PB9071 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF-C antibody |
|||
STJ96662 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to VEGF-C. |
![]() Anti-VEGF-B antibody |
|||
STJ96851 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to VEGF-B. |
![]() anti-VEGF Receptor 3 |
|||
YF-PA23727 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to VEGF Receptor 3 |
![]() anti-VEGF Receptor 1 |
|||
YF-PA11817 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to VEGF Receptor 1 |
![]() anti-VEGF Receptor 1 |
|||
YF-PA11818 | Abfrontier | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal to VEGF Receptor 1 |
![]() Anti-VEGF Neutralizing Antibody |
|||
79478-1 | BPS Bioscience | 50 µg | EUR 355 |
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species. |
![]() Anti-VEGF Neutralizing Antibody |
|||
79478-2 | BPS Bioscience | 100 g | EUR 460 |
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species. |
![]() VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled |
|||
AP-334-F | Alpha Diagnostics | 1 mg | Ask for price |
![]() anti-Cyclophilin F |
|||
YF-PA25484 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to Cyclophilin F |
![]() anti-Apolipoprotein F |
|||
YF-PA10244 | Abfrontier | 50 ul | EUR 435.6 |
Description: Mouse polyclonal to Apolipoprotein F |
![]() anti-Apolipoprotein F |
|||
YF-PA10245 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to Apolipoprotein F |
![]() anti-Apolipoprotein F |
|||
YF-PA10246 | Abfrontier | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal to Apolipoprotein F |
![]() anti-Cathepsin F |
|||
YF-PA15821 | Abfrontier | 50 ul | EUR 435.6 |
Description: Mouse polyclonal to Cathepsin F |
![]() anti-Cathepsin F |
|||
YF-PA15822 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to Cathepsin F |
![]() VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled |
|||
AP-336-F | Alpha Diagnostics | 1 mg | Ask for price |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-b-48T | DL Develop | 48T | EUR 591.6 |
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids. |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-b-96T | DL Develop | 96T | EUR 769.2 |
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids. |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Hu-48T | DL Develop | 48T | EUR 403.2 |
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Hu-96T | DL Develop | 96T | EUR 510 |
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Mu-48T | DL Develop | 48T | EUR 522 |
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Mu-96T | DL Develop | 96T | EUR 673.2 |
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Ra-48T | DL Develop | 48T | EUR 544.8 |
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
DLR-EG-VEGF-Ra-96T | DL Develop | 96T | EUR 704.4 |
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 619.2 |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 859.2 |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 396 |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 540 |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 536.4 |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 741.6 |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 564 |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RDR-EG-VEGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 781.2 |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-b-48Tests | Reddot Biotech | 48 Tests | EUR 592.8 |
![]() Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-b-96Tests | Reddot Biotech | 96 Tests | EUR 820.8 |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 380.4 |
![]() Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 517.2 |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 514.8 |
![]() Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 709.2 |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 540 |
![]() Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit |
|||
RD-EG-VEGF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 746.4 |
![]() VEGF |
|||
MO15067 | Neuromics | 500 ug | EUR 1092 |
![]() VEGF |
|||
LF-PR009 | Abfrontier | 10 ug | EUR 306 |
Description: VEGF protein |
![]() VEGF |
|||
PR15028 | Neuromics | 10 ug | EUR 553.2 |
![]() Anti-VEGF-A Humanized Antibody |
|||
A2136-100 | Biovision | 100 µg | EUR 612 |
![]() Anti-VEGF Rabbit Monoclonal Antibody |
|||
M00045-1 | BosterBio | 100ug/vial | EUR 476.4 |
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse. |
![]() Anti-VEGF Receptor 2 (2A2) |
|||
YF-MA13909 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 2 |
![]() Anti-VEGF Receptor 2 (4A2) |
|||
YF-MA13910 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 2 |
![]() Anti-VEGF Receptor 2 (2C5) |
|||
YF-MA13911 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 2 |
![]() Anti-VEGF Receptor 2 (4B5) |
|||
YF-MA13912 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 2 |
![]() Anti-VEGF Receptor 2 (4F1) |
|||
YF-MA13913 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 2 |
![]() Anti-VEGF Receptor 3 (5B6) |
|||
YF-MA10355 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (5F11) |
|||
YF-MA13094 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (6F9) |
|||
YF-MA13095 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (5B5) |
|||
YF-MA13096 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (4D1) |
|||
YF-MA13097 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (2E3) |
|||
YF-MA13098 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (1C1) |
|||
YF-MA13099 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF Receptor 3 (6B7) |
|||
YF-MA13100 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VEGF Receptor 3 |
![]() Anti-VEGF (Bevacizumab), humanized Antibody |
|||
A1045-100 | Biovision | each | EUR 601.2 |
![]() VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled |
|||
AP-335-F | Alpha Diagnostics | 1 mg | Ask for price |
![]() VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled |
|||
AP-338-F | Alpha Diagnostics | 1 mg | Ask for price |
![]() VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled |
|||
AP-339-F | Alpha Diagnostics | 1 mg | Ask for price |
![]() Mouse IgG F(c)-FITC conjugate (isotype control) |
|||
20008-Fc-F | Alpha Diagnostics | 100 ug | EUR 196.8 |
![]() Rabbit IgG F(c)-FITC conjugate, isotype control |
|||
20009-Fc-F | Alpha Diagnostics | 100 ug | EUR 196.8 |
![]() Goat IgG F(ab')2 fragment-FITC conjugate |
|||
20011-FAB2-F | Alpha Diagnostics | 100 tests | EUR 242.4 |
![]() Mouse IgG F(ab')2-FITC conjugate (isotype control) |
|||
20008-Fab2-F | Alpha Diagnostics | 100 ug | EUR 196.8 |
![]() Rabbit IgG F(ab')2-FITC conjugate, isotype control |
|||
20009-FAb2-F | Alpha Diagnostics | 100 ug | EUR 196.8 |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC041063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC041063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCAP1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCAP1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCB1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCB1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCP1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCR1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC941063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC941063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCA1063-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC811063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC811063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNUB1063-100 | Biotium | 100uL | EUR 250.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNUB1063-500 | Biotium | 500uL | EUR 549.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCH1063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNCH1063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC881063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC881063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC611063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC611063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC681063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC681063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC471063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC471063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC401063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC401063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC431063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC431063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC551063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC551063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC801063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC801063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC051063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC051063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC701063-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNC701063-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
![]() VEGF-A(VEGF/1063) Antibody |
|||
BNUM1063-50 | Biotium | 50uL | EUR 474 |
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL |
![]() VEGF/ Rat VEGF ELISA Kit |
|||
ELA-E0143r | Lifescience Market | 96 Tests | EUR 1063.2 |
![]() Anti-HLA-F Purified |
|||
11-823-C100 | ExBio | 0.1 mg | EUR 234 |
![]() Anti-Cyclin F Antibody |
|||
A06781 | BosterBio | 100ul | EUR 476.4 |
Description: Rabbit Polyclonal Cyclin F Antibody. Validated in IHC, WB and tested in Human. |
![]() Anti-HLA-F PE |
|||
1P-823-C100 | ExBio | 0.1 mg | EUR 397.2 |
![]() Anti-Cathepsin F antibody |
|||
PAab01307 | Lifescience Market | 100 ug | EUR 426 |
![]() Anti-Cystatin F antibody |
|||
PAab02182 | Lifescience Market | 100 ug | EUR 463.2 |
![]() Anti-HLA-F antibody |
|||
PAab03911 | Lifescience Market | 100 ug | EUR 494.4 |
![]() Anti-HLA-F antibody |
|||
PAab03912 | Lifescience Market | 100 ug | EUR 494.4 |
![]() anti- Cathepsin F antibody |
|||
FNab01307 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Cathepsin F |
![]() anti- Cystatin F antibody |
|||
FNab02182 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against Cystatin F |
![]() anti- HLA-F antibody |
|||
FNab03911 | FN Test | 100µg | EUR 702 |
Description: Antibody raised against HLA-F |
![]() anti- HLA-F antibody |
|||
FNab03912 | FN Test | 100µg | EUR 702 |
Description: Antibody raised against HLA-F |
![]() Anti-HLA-F antibody |
|||
STJ112420 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain. |
![]() Anti-APOBEC3D/F antibody |
|||
STJ91636 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to APOBEC3D/F. |
![]() Anti-Arylsulfatase F antibody |
|||
STJ91715 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Arylsulfatase F. |
![]() Anti-Cyclin F antibody |
|||
STJ92545 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Cyclin F. |
![]() Anti-Cyclophilin F antibody |
|||
STJ92550 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Cyclophilin F. |
![]() Anti-F beta antibody |
|||
STJ93162 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to FTbeta. |
![]() Anti-hnRNP F antibody |
|||
STJ93564 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to hnRNP F. |
![]() Anti-PIG-F antibody |
|||
STJ95089 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to PIG-F. |
![]() Anti-Cathepsin F antibody |
|||
STJ70694 | St John's Laboratory | 100 µg | EUR 430.8 |
![]() Anti-HLA-F antibody |
|||
STJ24030 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain. |
![]() Anti-Apolipoprotein F antibody |
|||
STJ71651 | St John's Laboratory | 100 µg | EUR 430.8 |
![]() Anti-Apolipoprotein F (1D5) |
|||
YF-MA10047 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to Apolipoprotein F |
![]() Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA |
|||
570-100-CUX | Alpha Diagnostics | Custom | Ask for price |
![]() Anti-VEGF Receptor 3/FLT4 Antibody |
|||
A01276-2 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF Receptor 3/FLT4 Antibody |
|||
A01276-3 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
A00534 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
A00534-1 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 2/KDR Antibody |
|||
A00901-2 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF Receptor 2/Kdr Antibody |
|||
A00901-3 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
PA1399 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
PA1966 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
PA1966-1 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 1/FLT1 Antibody |
|||
PA1966-2 | BosterBio | 100ug/vial | EUR 352.8 |
![]() Anti-VEGF Receptor 2/KDR Antibody |
|||
PA1989 | BosterBio | 100ug/vial | EUR 400.8 |
![]() Anti-VEGF Receptor 2/KDR Antibody |
|||
PB9429 | BosterBio | 100ug/vial | EUR 352.8 |
![]() VEGF antibody |
|||
70R-11863 | Fitzgerald | 100 ul | EUR 536.4 |
Description: Goat polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-11864 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-12327 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-12328 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-12329 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70-VR20 | Fitzgerald | 50 ug | EUR 392.4 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
10-2585 | Fitzgerald | 250 ug | EUR 590.4 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF antibody |
|||
10-2586 | Fitzgerald | 100 ug | EUR 289.2 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-13764 | Fitzgerald | 100 ug | EUR 418.8 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF Antibody |
|||
48707-100ul | SAB | 100ul | EUR 399.6 |
![]() VEGF Antibody |
|||
48707-50ul | SAB | 50ul | EUR 286.8 |
![]() VEGF protein |
|||
30R-AV008 | Fitzgerald | 2 ug | EUR 152.4 |
Description: Purified recombinant Murine VEGF protein |
![]() VEGF antibody |
|||
10R-7735 | Fitzgerald | 500 ug | EUR 678 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF antibody |
|||
10R-V101ax | Fitzgerald | 100 ug | EUR 571.2 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF antibody |
|||
10R-V101b | Fitzgerald | 200 ug | EUR 805.2 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF antibody |
|||
10R-V109A | Fitzgerald | 500 ug | EUR 327.6 |
Description: Mouse monoclonal VEGF antibody |
![]() VEGF Antibody |
|||
ABF5131 | Lifescience Market | 100 ug | EUR 525.6 |
![]() VEGF antibody |
|||
70R-VG001 | Fitzgerald | 100 ug | EUR 392.4 |
Description: Affinity purified Goat polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-VR001x | Fitzgerald | 50 ug | EUR 392.4 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-VR003 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-VR004 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
70R-VR006 | Fitzgerald | 50 ug | EUR 327.6 |
Description: Affinity purified Rabbit polyclonal VEGF antibody |
![]() VEGF antibody |
|||
PAab09933 | Lifescience Market | 100 ug | EUR 463.2 |
![]() VEGF, CF |
|||
PR15028CF | Neuromics | 10 ug | EUR 553.2 |
![]() VEGF 121 |
|||
PR15029 | Neuromics | 5 ug | EUR 498 |
![]() VEGF 162 |
|||
PR15030 | Neuromics | 25 ug | EUR 553.2 |